Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis
08 Febrero 2024 - 6:30AM
Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health,
hospice and high-acuity care in the home, is now offering advanced
molecular testing to its care centers nationwide. This innovative
collaboration with Patient Choice Laboratories utilizes molecular
testing for the swift and precise identification of pathogens in
urine, respiratory and wound infections. By leveraging the latest
in diagnostic technology, Amedisys aims to improve the quality of
infection testing, ultimately facilitating better patient care and
outcomes.
Advanced molecular testing revolutionizes the diagnosis and
management of infections, as it delivers rapid and precise results,
ultimately enabling quicker initiation of appropriate treatment
interventions. With improved accuracy, sensitivity and specificity,
molecular testing significantly enhances the ability to identify
infectious pathogens, supporting timely and targeted care
strategies.
“We are excited to integrate molecular testing capabilities into
our infection diagnosis protocols,” states Cyndi Shook, Senior Vice
President of Clinical Operations at Amedisys. “This advancement
represents a significant step in our ongoing commitment to
providing the highest quality of care to our patients. By
leveraging the latest in diagnostic technology, we can further
enhance the accuracy and speed of infection testing, allowing us to
tailor treatment plans to the individual needs of each
patient.”
“Patients Choice Laboratories is excited to partner with
Amedisys, one of the leaders in the home health industry, in an
effort to improve outcomes for patients suffering from infectious
diseases,” said Brad Moss, President at Patients Choice
Laboratories. “Our automated pre-analytical, analytical and
post-analytical processes in molecular technologies provide the
necessary clinical decision support so that treatments are targeted
and successful.”
“According to the CDC, more than one-third of deaths of people
over the age of 65 are caused by infectious diseases, thus making
turnaround time critical so that the most appropriate treatment(s)
are deployed in the early stages of infection,” added Thomas Payne,
Chief Operations Officer at Patients Choice Laboratories.
“Molecular testing provides the speed and accuracy needed to detect
pathogens across our entire infectious disease platform.”
“Our partnership with Patient Choice Laboratories aligns
seamlessly with our dedication to delivering exceptional care and
optimizing patient outcomes,” added Barbara Andazola, Vice
President of Clinical Practice, Strategy and Programs at Amedisys.
“By incorporating molecular testing into our infection diagnosis
protocols, we are empowering our care teams to provide more
accurate and effective treatments, ultimately reducing the impact
of infections and preventing related hospitalizations.”
Amedisys has implemented comprehensive protocols and training to
ensure seamless integration of molecular testing into its care
centers. The rollout of this innovative approach to infection
diagnosis underscores the organization’s commitment to staying at
the forefront of healthcare advancements and technology, ultimately
providing its patients with the highest standard of care and
support.
For more information about Amedisys Home Health and its advanced
molecular testing capabilities, please visit www.amedisys.com.
About Amedisys: Amedisys, Inc. is a leading
healthcare at home company delivering personalized home health,
hospice and high-acuity care services. Amedisys is focused on
delivering the care that is best for our patients, whether that is
inpatient hospital, palliative, and skilled nursing facility
(“SNF”) care in their homes; home-based recovery and rehabilitation
after an operation or injury; care focused on empowering them to
manage a chronic disease; or hospice care at the end of life.
Nearly 3,000 hospitals and more than 110,000 physicians nationwide
have chosen Amedisys as a partner in post-acute care. Founded in
1982, headquartered in Baton Rouge, LA with an executive office in
Nashville, TN, Amedisys is a publicly held company. With
approximately 19,000 employees in 521 care centers in 37 states and
the District of Columbia, Amedisys is dedicated to delivering the
highest quality of care to the doorsteps of nearly 470,000 patients
in need every year, performing more than 10.6 million visits
annually. For more information about the Company, please visit:
www.amedisys.com.
About Patients Choice Laboratories:Patients
Choice Laboratories (PCL), a CLIA certified and CAP accredited
laboratory based in Indianapolis, Indiana, is a leading provider of
comprehensive laboratory testing throughout the United States.
Since 2013 PCL has served patients and providers with a focus on
fast, accurate, and reliable results. Utilizing innovative
molecular technology, PCL provides specific results allowing for
quick diagnoses and treatment of patients. PCL can provide
treatment recommendations based on antibiotic-resistant genes to
improve antimicrobial stewardship and patient outcomes. PCL is at
the forefront of infectious diseases, clinical labs,
pharmacogenetics, and toxicology to ensure the health of our
communities now and into the future. Learn more about how we are
pioneering new ways to provide patient care on our website:
pclabsdx.com.
Contact: |
|
|
Nick Muscato |
|
Kendra Kimmons |
Amedisys, Inc. |
|
Amedisys, Inc. |
Chief Strategy Officer |
|
Media Relations |
615.928.5452 |
|
225.299.3720 |
nick.muscato@amedisys.com |
|
Kendra.kimmons@amedisys.com |
Amedisys (NASDAQ:AMED)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Amedisys (NASDAQ:AMED)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024